Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVM149 vs Salmeterol/Fluticasone in Asthma
NCT03063086Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Countries
- 6
01
Overview
A Phase 2 trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in asthma, sponsored by Novartis. Started Jan 2017; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03063086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03063086.